Literature DB >> 17101792

An inhibitor of the kinesin spindle protein activates the intrinsic apoptotic pathway independently of p53 and de novo protein synthesis.

Weikang Tao1, Victoria J South, Ronald E Diehl, Joseph P Davide, Laura Sepp-Lorenzino, Mark E Fraley, Kenneth L Arrington, Robert B Lobell.   

Abstract

The kinesin spindle protein (KSP), a microtubule motor protein, is essential for the formation of bipolar spindles during mitosis. Inhibition of KSP activates the spindle checkpoint and causes apoptosis. It was shown that prolonged inhibition of KSP activates Bax and caspase-3, which requires a competent spindle checkpoint and couples with mitotic slippage. Here we investigated how Bax is activated by KSP inhibition and the roles of Bax and p53 in KSP inhibitor-induced apoptosis. We demonstrate that small interfering RNA-mediated knockdown of Bax greatly attenuates KSP inhibitor-induced apoptosis and that Bax activation is upstream of caspase activation. This indicates that Bax mediates the lethality of KSP inhibitors and that KSP inhibition provokes apoptosis via the intrinsic apoptotic pathway where Bax activation is prior to caspase activation. Although the BH3-only protein Puma is induced after mitotic slippage, suppression of de novo protein synthesis that abrogates Puma induction does not block activation of Bax or caspase-3, indicating that Bax activation is triggered by a posttranslational event. Comparison of KSP inhibitor-induced apoptosis between matched cell lines containing either functional or deficient p53 reveals that inhibition of KSP induces apoptosis independently of p53 and that p53 is dispensable for spindle checkpoint function. Thus, KSP inhibitors should be active in p53-deficient tumors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17101792      PMCID: PMC1800817          DOI: 10.1128/MCB.01505-06

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  41 in total

1.  Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity.

Authors:  P Bouillet; D Metcalf; D C Huang; D M Tarlinton; T W Kay; F Köntgen; J M Adams; A Strasser
Journal:  Science       Date:  1999-11-26       Impact factor: 47.728

2.  Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen.

Authors:  T U Mayer; T M Kapoor; S J Haggarty; R W King; S L Schreiber; T J Mitchison
Journal:  Science       Date:  1999-10-29       Impact factor: 47.728

3.  BUBR1 phosphorylation is regulated during mitotic checkpoint activation.

Authors:  W Li; Z Lan; H Wu; S Wu; J Meadows; J Chen; V Zhu; W Dai
Journal:  Cell Growth Differ       Date:  1999-11

4.  Mutation of a gene that encodes a kinesin-like protein blocks nuclear division in A. nidulans.

Authors:  A P Enos; N R Morris
Journal:  Cell       Date:  1990-03-23       Impact factor: 41.582

5.  Mutations in the kinesin-like protein Eg5 disrupting localization to the mitotic spindle.

Authors:  K E Sawin; T J Mitchison
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

6.  Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations.

Authors:  M Monzó; R Rosell; J J Sánchez; J S Lee; A O'Brate; J L González-Larriba; V Alberola; J C Lorenzo; L Núñez; J Y Ro; C Martín
Journal:  J Clin Oncol       Date:  1999-06       Impact factor: 44.544

7.  Monoclonal antibodies to mitotic cells.

Authors:  F M Davis; T Y Tsao; S K Fowler; P N Rao
Journal:  Proc Natl Acad Sci U S A       Date:  1983-05       Impact factor: 11.205

8.  Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex.

Authors:  J I-Ju Leu; Patrick Dumont; Michael Hafey; Maureen E Murphy; Donna L George
Journal:  Nat Cell Biol       Date:  2004-04-11       Impact factor: 28.824

9.  Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy.

Authors:  Maria Castedo; Jean-Luc Perfettini; Thomas Roumier; Alexander Valent; Hana Raslova; Kenichi Yakushijin; David Horne; Jean Feunteun; Gilbert Lenoir; René Medema; William Vainchenker; Guido Kroemer
Journal:  Oncogene       Date:  2004-05-27       Impact factor: 9.867

10.  Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5.

Authors:  T M Kapoor; T U Mayer; M L Coughlin; T J Mitchison
Journal:  J Cell Biol       Date:  2000-09-04       Impact factor: 10.539

View more
  22 in total

1.  A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors.

Authors:  Kyle Holen; Robert DiPaola; Glenn Liu; Antoinette R Tan; George Wilding; Karl Hsu; Nancy Agrawal; Cong Chen; Lingling Xue; Elizabeth Rosenberg; Mark Stein
Journal:  Invest New Drugs       Date:  2011-03-22       Impact factor: 3.850

2.  The expression of Eg5 predicts a poor outcome for patients with renal cell carcinoma.

Authors:  Dingqi Sun; Jiaju Lu; Kejia Ding; Dongbin Bi; Zhihong Niu; Qingwei Cao; Jie Zhang; Sentai Ding
Journal:  Med Oncol       Date:  2013-02-01       Impact factor: 3.064

3.  Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells.

Authors:  B Z Carter; D H Mak; R Woessner; S Gross; W D Schober; Z Estrov; H Kantarjian; M Andreeff
Journal:  Leukemia       Date:  2009-05-21       Impact factor: 11.528

4.  A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial.

Authors:  Christopher W Lee; Karl Bélanger; Sanjay C Rao; Teresa M Petrella; Richard G Tozer; Lori Wood; Kerry J Savage; Elizabeth A Eisenhauer; Timothy W Synold; Nancy Wainman; Lesley Seymour
Journal:  Invest New Drugs       Date:  2007-10-26       Impact factor: 3.850

5.  A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors.

Authors:  Howard A Burris; Suzanne F Jones; Daphne D Williams; Steven J Kathman; Jeffrey P Hodge; Lini Pandite; Peter T C Ho; Scott A Boerner; Patricia Lorusso
Journal:  Invest New Drugs       Date:  2010-01-13       Impact factor: 3.850

6.  Activity of the kinesin spindle protein inhibitor ispinesib (SB-715992) in models of breast cancer.

Authors:  James W Purcell; Jefferson Davis; Mamatha Reddy; Shamra Martin; Kimberly Samayoa; Hung Vo; Karen Thomsen; Peter Bean; Wen Lin Kuo; Safiyyah Ziyad; Jessica Billig; Heidi S Feiler; Joe W Gray; Kenneth W Wood; Sylvaine Cases
Journal:  Clin Cancer Res       Date:  2010-01-12       Impact factor: 12.531

7.  Quantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fate.

Authors:  James D Orth; Yangzhong Tang; Jade Shi; Clement T Loy; Christiane Amendt; Claudia Wilm; Frank T Zenke; Timothy J Mitchison
Journal:  Mol Cancer Ther       Date:  2008-10-30       Impact factor: 6.261

8.  KIF11 inhibition for glioblastoma treatment: reason to hope or a struggle with the brain?

Authors:  Silvia Valensin; Chiara Ghiron; Claudia Lamanna; Andreas Kremer; Marco Rossi; Pietro Ferruzzi; Marco Nievo; Annette Bakker
Journal:  BMC Cancer       Date:  2009-06-22       Impact factor: 4.430

9.  KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells.

Authors:  Ki Hyung Kim; Yanhua Xie; Ewan M Tytler; Richard Woessner; Gil Mor; Ayesha B Alvero
Journal:  J Transl Med       Date:  2009-07-20       Impact factor: 5.531

10.  p53 suppresses structural chromosome instability after mitotic arrest in human cells.

Authors:  W B Dalton; B Yu; V W Yang
Journal:  Oncogene       Date:  2010-01-11       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.